Fig. 3. Different phospholipase C (PLC) inhibitors affect exogenous and endogenous
lipase activities. (A) Western blot probed with anti-A and anti-B antisera.
Lane 1, supernatant from sham-treated pellicle; lane 2, supernatant from
PLC-treated pellicle; lane 3, supernatant from phospholipase C (PLC)-treated
pellicle with 2-nitro-4-carboxyphenyl-N,N-diphenylcarbamate (NCDC)
and phenylmethanesulfonyl fluoride (PMSF); lane 4, supernatant of PLC-treated
pellicle with p-chloromercuriphenylsulfonic acid (PCMPSA); lane 5,
salt/ethanol wash proteins; lane 6, proteins from salt/ethanol wash in the
presence of NCDC and PMSF; lane 7, proteins from salt/ethanol wash in the
presence of PCMPSA. (B) Same as A but probed with
anti-cross-reacting-determinant (anti-CRD) antiserum. The open arrow points to
40-60 kDa proteins. Surface antigens (>200 kDa) are best seen in lanes A2,
A4, A5 and B2. Other proteins of interest are between 40 and 60 kDa. Gels were
8 % polyacrylamide.
